[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Zeuzem et al., 2015 - Google Patents

Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a …

Zeuzem et al., 2015

View PDF
Document ID
4468021119940354014
Author
Zeuzem S
Ghalib R
Reddy K
Pockros P
Ari Z
Zhao Y
Brown D
Wan S
DiNubile M
Nguyen B
Robertson M
Wahl J
Barr E
Butterton J
Publication year
Publication venue
Annals of internal medicine

External Links

Snippet

Background: Novel interferon-and ribavirin-free regimens are needed to treat hepatitis C virus (HCV) infection. Objective: To evaluate the safety and efficacy of grazoprevir (NS3/4A protease inhibitor) and elbasvir (NS5A inhibitor) in treatment-naive patients. Design …
Continue reading at citeseerx.ist.psu.edu (PDF) (other versions)

Classifications

    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/34Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/36Computer-assisted acquisition of medical data, e.g. computerised clinical trials or questionnaires
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06QDATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10Services
    • G06Q50/22Health care, e.g. hospitals; Social work
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/576Immunoassay; Biospecific binding assay for hepatitis
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F21/00Security arrangements for protecting computers, components thereof, programs or data against unauthorised activity

Similar Documents

Publication Publication Date Title
Zeuzem et al. Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial
Falade-Nwulia et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review
Everson et al. Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial
Burstow et al. Hepatitis C treatment: where are we now?
Stedman Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential
Dore et al. Elbasvir–grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial
Armstrong et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002
Bacon et al. Boceprevir for previously treated chronic HCV genotype 1 infection
Backus et al. Comparative effectiveness of ledipasvir/sofosbuvir±ribavirin vs. ombitasvir/paritaprevir/ritonavir+ dasabuvir±ribavirin in 6961 genotype 1 patients treated in routine medical practice
Sherman et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy
Backus et al. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large US cohort
Rose et al. Sofosbuvir: a nucleotide NS5B inhibitor for the treatment of chronic hepatitis C infection
Alao et al. Baseline intrahepatic and peripheral innate immunity are associated with hepatitis C virus clearance during direct‐acting antiviral therapy
Chang et al. Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease
Meissner Update in HIV–hepatitis C virus coinfection in the direct acting antiviral era
Weisberg et al. A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection
Childs-Kean et al. Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C
Re III et al. Determinants of liver complications among HIV/hepatitis B virus–coinfected patients
Machado et al. Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study
Florian et al. Direct‐acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now
Lagging et al. Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations
Jaroszewicz et al. Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA
Łucejko et al. Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection
Rosenthal et al. Sofosbuvir and ledipasvir for HIV/HCV co-infected patients
Ogawa et al. Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C